Emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD), is a debilitating condition that causes irreversible damage to lung tissue making breathing difficult.

Emphysema is a type of Chronic Obstructive Pulmonary Disease (COPD) where the tiny air sacs (alveoli) at the end of the larger airways (bronchi) are damaged and enlarged, reducing the ability of the lungs to take in oxygen and remove carbon dioxide.  The main symptom of emphysema is shortness of breath that worsens over time.

Emphysema is diagnosed by a Pulmonologist using pulmonary function tests (PFTs) and often includes a CT scan of your lungs. While emphysema is not reversible, it is treatable. Treatment options depend on many factors and you should consult your Pulmonologist to decide what treatment is best for you. 

BTG’s flagship Interventional Pulmonology product are called PneumRx® Coils.  In October of 2014, enrollment for the 315-subject Coil pivotal trial at 26 sites in the United States, Canada and Europe was completed. RENEW is a randomized controlled study with a primary endpoint of improvement in 6 Minute Walk Test from baseline to 12 months, comparing PneumRx® Coil treatment to standard of care. 

This information is not intended as, nor does it constitute, medical advice or diagnosis. Always seek the advice of physicians or other qualified health providers with any questions regarding a medical condition. Users should never disregard professional medical advice or delay in seeking it because of something on this website.


The PneumRx® Endobronchial Coil System is an investigational device in the United States, limited by United States law to investigational use.

The PneumRx® Endobronchial Coil System is not available for commercial sale in the United States.